MedTrace Logo

Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

NCT01428427 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2017-11-13

No results posted yet for this study

Summary

MEK112111 is a dose-escalation, Phase IB, open-label, single-arm, multi-center study. The primary objective of the study is to determine the recommended dose and regimen for the orally administered MEK inhibitor GSK1120212 dosed in combination with gemcitabine in subjects with solid tumors.

Conditions

  • Leukaemia, Myelocytic, Acute

Interventions

DRUG

GSK1120212

Continuous daily oral dosing while on study or disease progression (cycle = 28 days).

DRUG

Gemcitabine

Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-12
Primary Completion
2011-07-18
Completion
2011-07-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01428427 on ClinicalTrials.gov